Fifth diabetes medicine recalled for containing too much of a ‘probable carcinogen’
Thursday, Lupin Pharmaceuticals announced its recall of Metformin Hydrochloride Extended-Release Tablets after the FDA found the Type 2 diabetes medicine exceeded standards for NDMA.
Though NDMA (N-Nitrosodimethylamine) occurs naturally in many foods, the FDA has a limit on how much should be ingested daily because it’s classified as a “probable human carcinogen.” The FDA said earlier this month it had asked five companies to voluntarily recall its Metformin after testing turned up too much NDMA.
Apotex, Amneal, Teva and Marksans Pharma previously pulled their Metformin extended release tablets. Lupin completes the list with its recall of 500 mg tablets, lot No. G901203, with an expiration date of 12/2020. The NDC numbers on the label is No. 68180-336-07.
Those taking Metformin should keep taking it until deciding on another treatment with your doctor or pharmacist. Advice from the FDA for Metformin patients can be found on the FDA’s website as well as a place to report problems with this or any other drug.
Anyone in the drug chain from wholesalers down to consumers should call Inmar Rx Solutions at 855-532-1856 to return recalled Metformin or to get questions about this recall answered.
This story was originally published June 11, 2020 at 5:09 PM with the headline "Fifth diabetes medicine recalled for containing too much of a ‘probable carcinogen’."
